Zydus Lifesciences ZYDUSLIFE
Diversified major: US generics (~45% of sales), India branded formulations, consumer wellness, vaccines/biosimilars and an in-house NCE pipeline
Mapped in 1 theme: Pharmaceuticals.
Where Zydus Lifesciences sits in the supply chain
Zydus Lifesciences appears in 4 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Pharmaceuticals › Specialty & innovation (R&D)
OwnerOther companies in this layer
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Pharmaceuticals › Biosimilars, vaccines & biologics
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 19,547 | 23,242 | 27,148 |
| Net profit | 3,973 | 4,673 | 5,124 |
Latest-year revenue ₹27,148 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Rare Indian NCE track record - saroglitazar (Lipaglyn) and desidustat discovered in-house
- Strong US limited-competition products (gMyrbetriq/mirabegron, transdermals, injectables)
- Consumer wellness (Complan, Glucon-D, Nycil) and launched generic semaglutide in India (Mar 2026)
Risks
- US earnings concentration in a few products, including mirabegron with patent-litigation risk
- US generic tariff clock from Aug 2028 without US manufacturing
- NCE development spend with binary outcomes (saroglitazar PBC trials)
Common questions
What does Zydus Lifesciences do?
Diversified major: US generics (~45% of sales), India branded formulations, consumer wellness, vaccines/biosimilars and an in-house NCE pipeline.
Where does Zydus Lifesciences sit in the supply chain?
Zydus Lifesciences (NSE: ZYDUSLIFE) is mapped in 4 supply-chain layers: India branded formulations (Pharmaceuticals); Specialty & innovation (R&D) (Pharmaceuticals); Generics (US & export) (Pharmaceuticals); and Biosimilars, vaccines & biologics (Pharmaceuticals).
Who are Zydus Lifesciences' peers?
In the Generics (US & export) layer of Pharmaceuticals: Dr Reddy's Laboratories, Aurobindo Pharma, Lupin, Cipla, Sun Pharmaceutical Industries, Alembic Pharmaceuticals and 6 more.
What is Zydus Lifesciences' market cap and valuation?
As of 30 Oct 2026: market cap ₹1.24L Cr, P/E 25.5x, ROCE 21.1%, ROE 21.2%, dividend yield 0.08%.